Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin’s Lymphoma
29 Novembre 2021 - 1:00PM
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing first-in-class allogeneic gamma delta T
cell therapies for cancer and other diseases, today announced that
the Company will host a webcast presentation on Monday, December 6,
2021 at 8:30 AM EST to discuss interim data from its dose
escalation Phase 1 study evaluating the safety and tolerability of
ADI-001, Adicet’s investigational first-in-class allogeneic gamma
delta CAR T cell therapy targeting CD20 for the potential treatment
of B Cell Non-Hodgkin’s Lymphoma.
The event will feature Sattva S. Neelapu, M.D., Professor in the
Department of Lymphoma-Myeloma at The University of Texas MD
Anderson Cancer Center, alongside members of the Adicet management
team.
Conference Call and Webcast Event
A live webcast of the presentation can be accessed under
“Presentations & Events” in the investors section of the
Company’s website at www.adicetbio.com. The archived webcast will
be available on the Company's website beginning approximately two
hours after the event.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer and
other diseases. Adicet is advancing a pipeline of “off-the-shelf”
gamma delta T cells, engineered with chimeric antigen receptors and
T cell receptor-like targeting moieties to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in patients.
For more information, please visit our website at
http://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to business and operations of Adicet
including, but not limited to, the interim clinical data resulting
from studies with ADI-001, including future plans or expectations,
as well as the expected potential therapeutic effects, safety
profile, expectations regarding the initiation, design,
implementation, timing, and success of future clinical studies of
ADI-001 and expectations regarding its other CAR gamma delta T cell
therapy development activities.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs of future events
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements,
including, without limitation, the effect of COVID-19 on our
business and financial results, including with respect to
disruptions to our clinical trials, business operations, and
ability to raise additional capital; Adicet's ability to execute on
its strategy; that positive results from a clinical study may not
necessarily be predictive of the results of future or ongoing
clinical studies; that future clinical studies may fail to
demonstrate adequate safety and efficacy of our product candidates,
which would prevent, delay, or limit the scope of regulatory
approval and commercialization; that regulatory approval processes
of the FDA and comparable foreign regulatory authorities are
lengthy, time–consuming, and inherently unpredictable; regulatory
developments in the United States and foreign countries;
and the company's estimates regarding expenses, future revenue, and
capital requirements. For a discussion of these and
other risks and uncertainties, and other important factors, any of
which could cause Adicet's actual results to differ from those
contained in the forward-looking statements, see the section
entitled "Risk Factors" in Adicet's most recent annual report on
Form 10-K and our subsequent quarterly reports on Form 10-Q and
current reports on Form 8-K filed with the Securities and
Exchange Commission (the “SEC”), as well as discussions of
potential risks, uncertainties, and other important factors in
Adicet's other filings with the SEC. All information in this
press release is as of the date of the release, and Adicet
undertakes no duty to update this information unless required by
law.
Adicet Bio, Inc.Investor and Media
ContactsAnne Bowdidgeabowdidge@adicetbio.com
Janhavi MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@sternir.com
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Lug 2023 a Lug 2024